MX2017009281A - Antihistamina para usar en el tratamiento de cancer de seno. - Google Patents

Antihistamina para usar en el tratamiento de cancer de seno.

Info

Publication number
MX2017009281A
MX2017009281A MX2017009281A MX2017009281A MX2017009281A MX 2017009281 A MX2017009281 A MX 2017009281A MX 2017009281 A MX2017009281 A MX 2017009281A MX 2017009281 A MX2017009281 A MX 2017009281A MX 2017009281 A MX2017009281 A MX 2017009281A
Authority
MX
Mexico
Prior art keywords
treatment
breast cancer
antihistamine
ebastin
desloratadine
Prior art date
Application number
MX2017009281A
Other languages
English (en)
Inventor
Olsson Hakan
Einefors Rickard
Original Assignee
Belina Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belina Pharma Ab filed Critical Belina Pharma Ab
Publication of MX2017009281A publication Critical patent/MX2017009281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe en el presente documento la desloratadina o ebastina para usarse en el tratamiento de un paciente diagnosticado con cáncer de seno. También se describe la desloratadina o ebastina para usarse en el tratamiento de un paciente diagnosticado con un tipo de cáncer susceptible a inmunoterapia.
MX2017009281A 2015-01-19 2016-01-19 Antihistamina para usar en el tratamiento de cancer de seno. MX2017009281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1550036 2015-01-19
PCT/EP2016/051000 WO2016116438A1 (en) 2015-01-19 2016-01-19 Antihistamine for use in treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2017009281A true MX2017009281A (es) 2018-02-09

Family

ID=55174654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009281A MX2017009281A (es) 2015-01-19 2016-01-19 Antihistamina para usar en el tratamiento de cancer de seno.

Country Status (15)

Country Link
US (1) US10456388B2 (es)
EP (1) EP3247356B1 (es)
JP (1) JP6745805B2 (es)
KR (1) KR102387840B1 (es)
CN (1) CN107249587B (es)
AU (1) AU2016208673B2 (es)
BR (1) BR112017015013A2 (es)
CA (1) CA2973913C (es)
ES (1) ES2841981T3 (es)
IL (1) IL253533B (es)
MX (1) MX2017009281A (es)
PL (1) PL3247356T3 (es)
RU (1) RU2017129056A (es)
WO (1) WO2016116438A1 (es)
ZA (1) ZA201704634B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240131015A1 (en) 2019-10-17 2024-04-25 Belina Pharma Ab Medicament for treatment and/or prophylactic treatment of cancers
US20220387412A1 (en) * 2019-11-04 2022-12-08 University Of Kentucky Research Foundation Novel Superebastine Against Therapy Resistant Prostate Cancer
CN110755431B (zh) * 2019-11-08 2023-02-28 暨南大学 地氯雷他定在制备抗肝癌药物中的应用
WO2022055408A1 (en) 2020-09-10 2022-03-17 Belina Pharma Ab Desloratadine or loratadine for use in the treatment of breast cancer
CN114432446B (zh) * 2020-11-05 2023-07-04 南湖实验室 抗组胺药在制备抗肿瘤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
US20040072824A1 (en) 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
FR2825279B1 (fr) 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
CA2465916A1 (en) 2001-11-09 2003-05-15 The University Of Manitoba Treatment of breast cancer
AU2003219160A1 (en) 2003-03-12 2004-09-30 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
JP2008526895A (ja) * 2005-01-21 2008-07-24 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なイミダゾールおよびベンゾイミダゾール誘導体
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
US20130263297A1 (en) * 2010-11-10 2013-10-03 Cedars-Sinai Medical Center Methods of treating cancer
RU2490028C1 (ru) 2012-01-26 2013-08-20 Михаил Аркадьевич Шурдов Способ лечения онкологических заболеваний
WO2014018563A2 (en) 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
CN103830208A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 含有h1受体拮抗剂的吸入制剂
CN103044395B (zh) 2012-12-31 2015-03-11 天津药物研究院 含有地氯雷他定结构的氨基酸类衍生物、其制备方法和用途
CN104292211A (zh) 2013-07-15 2015-01-21 天津药物研究院 地氯雷他定类一氧化氮供体及其制备方法和用途

Also Published As

Publication number Publication date
AU2016208673A1 (en) 2017-09-07
CN107249587B (zh) 2021-04-23
KR102387840B1 (ko) 2022-04-18
WO2016116438A1 (en) 2016-07-28
US20180008588A1 (en) 2018-01-11
EP3247356A1 (en) 2017-11-29
PL3247356T3 (pl) 2021-05-04
JP2018502125A (ja) 2018-01-25
IL253533A0 (en) 2017-09-28
ES2841981T3 (es) 2021-07-12
RU2017129056A (ru) 2019-02-21
CN107249587A (zh) 2017-10-13
BR112017015013A2 (pt) 2018-01-23
ZA201704634B (en) 2021-06-30
JP6745805B2 (ja) 2020-08-26
CA2973913A1 (en) 2016-07-28
RU2017129056A3 (es) 2019-07-17
KR20170104499A (ko) 2017-09-15
EP3247356B1 (en) 2020-10-07
CA2973913C (en) 2021-12-14
AU2016208673B2 (en) 2021-04-01
US10456388B2 (en) 2019-10-29
IL253533B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
GEP20217331B (en) Anti-tigit antibodies
EP3094752A4 (en) Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
IL263678B (en) Compounds for use in the treatment of breast cancer +ar
EA201400178A1 (ru) Лечение рака молочной железы
IL248487A0 (en) Methods for treating early breast cancer with trastuzumab-dmi-mcc and pertuzumab
IL251761A0 (en) Cancer treatment with immune system stimulants
GEP201706612B (en) Methods for the treatment of breast cancer
MX2017009281A (es) Antihistamina para usar en el tratamiento de cancer de seno.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
PH12019500135A1 (en) Methods of treating prostate cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
HUE055143T2 (hu) Kortexolon 17alfa-valerát daganatok kezelésében történõ alkalmazásra
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
ZA201802452B (en) New therapeutic strategies against blood cancer
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX2017000306A (es) Metodos para tratar hipotension.
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
MX2016010838A (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
EP3154438A4 (en) Therapeutic ultrasound breast treatment
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
GB201409363D0 (en) Skin cancer treatment
MX2017005807A (es) Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.
EP3151821A4 (en) Marmelin analogs and methods of use in cancer treatment
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.